The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Imaging biomarkers of NAFLD, NASH, and fibrosis
Open accessAbstract
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic entity that requires a liver biopsy assessment to diagnose the progressive form of NAFLD called non-alcoholic steatohepatitis (NASH). Liver biopsy is invasive, subject to sampling and interobserver variability, and impractical to scale to the affected population of up to 1 billion affected individuals worldwide. Non-invasive imaging biomarkers have emerged as a key modality to address the major unmet need to diagnose, stage, and longitudinally monitor NAFLD. SCOPE OF REVIEW: In this review, we critically examine the use of non-invasive imaging biomarkers to diagnose NAFLD, NASH, and fibrosis stage. MAJOR CONCLUSIONS: Ultrasound and magnetic resonance imaging (MRI) biomarkers of liver fat can diagnose NAFLD. MRI proton density fat fraction (MRI-PDFF) is better than liver biopsy, particularly for following longitudinal changes in liver fat in clinical trials. Imaging biomarkers to reliably diagnose NASH are under investigation, but when used alone, continue to have only modest diagnostic accuracy. However, the fibrosis stage has the strongest association with liver decompensation and mortality, and elastography has emerged as a reliable biomarker for liver fibrosis. We review the combination of biomarkers to risk stratify patients and identify individuals needing treatment and the implications of longitudinal changes in liver stiffness measurement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“Distinguishing between NAFL and NASH depends on identifying pathologic features of liver histology, namely steatosis plus lobular inflammation and hepatocyte ballooning typically in zone 3 with or without peri-sinusoidal fibrosis [2].”
BackgroundChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235 · cited 1×
“NAFLD is increasingly common with rising prevalence in parallel with the global epidemic of obesity-related metabolic syndrome [4,5].”
BackgroundDulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965
Self-citationKarlas, T., Petroff, D., Sasso, M., Fan, J.-G., Mi, Y.-Q., de Lédinghen, V., Kumar, M., Lupsor-Platon, M., Han, K.-H., Cardoso, A. C., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.022 · Cited by 1,275 · cited 2×
“Advantages of CAP include that it is a rapid, point-of-care assessment with good sensitivity and specificity for diagnosing fatty liver [20].”
BackgroundMethodNoureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · cited 1×
“In a longitudinal assessment, MRI-PDFF was more accurate at detecting changes in liver fat than liver biopsy [36] and has been validated in multiple studies [37].”
MethodSelf-citationLiver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, A. W.-H., Chermak, F., Choi, P. C.-L., Merrouche, W., Chu, S. H.-T., Pesque, S., et al. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.331 · Cited by 345 · cited 1×
“Implementing the XL probe decreased the failure rate associated with FibroScan in NAFLD patients [53].”
BackgroundHaldar, D., Kern, B., Hodson, J., Armstrong, M. J., Adam, R., Berlakovich, G., Fritz, J., Feurstein, B., Popp, W., Karam, V., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.011 · Cited by 313
Stine, J. G., Munaganuru, N., Barnard, A., Wang, J. L., Kaulback, K., Argo, C. K., Singh, S., Fowler, K. J., Sirlin, C. B., & Loomba, R. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.061 · Cited by 283
Self-citation
Cited by
Hepatic fibrosis 2022: Unmet needs and a blueprint for the future
Friedman, S. L., & Pinzani, M. (2022) · Hepatology · doi:10.1002/hep.32285 · Cited by 430
“Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis.”
BackgroundInfluentialNAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
Mantovani, A., Byrne, C. D., & Targher, G. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00261-2 · Cited by 230
Treatment Candidacy for Pharmacologic Therapies for NASH
Rowe, I. A., Wong, V. W.-S., & Loomba, R. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.03.005 · Cited by 41
Self-citation
Metadata
- Authors
- Ajmera, V., & Loomba, R.
- Venue
- Molecular Metabolism
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 50
- Pages
- 101167
- ISSN
- 2212-8778 (ISSN-L)
- OpenAlex
- W3119859060
- Cited by
- 213
- References
- 13
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Imaging biomarkers of NAFLD, NASH, and fibrosis. https://app.cochat.ai/papers/10.1016/j.molmet.2021.101167
- The paper
- Ajmera, V., & Loomba, R. (2021). Imaging biomarkers of NAFLD, NASH, and fibrosis. Molecular Metabolism. https://doi.org/10.1016/j.molmet.2021.101167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.